Press Release

Lund, Sweden – May 5, 2026

ImmuneBiotech Achieves Strategic Breakthrough in China’s “Medical Silicon Valley” with Launch of GutMagnific® and Early Commercial Traction

Entry into Hainan’s Boao Lecheng Pilot Zone, combined with clinical integration and initial market execution, marks a major step in the company’s global expansion strategy

ImmuneBiotech Medical Sweden AB, a pioneer in precision probiotics and microbiome-based therapeutics, today announces a significant strategic milestone in China, marked by the successful launch of its flagship product, GutMagnific®, within Hainan province (South China). The introduction has been achieved through a highly selective commercial collaboration, enabling both clinical integration and early commercial deployment within one of the world’s most advanced healthcare innovation environments.

Entry into China’s “Medical Silicon Valley”

The launch takes place within the Boao Lecheng International Medical Tourism Pilot Zone, widely referred to as China’s “Medical Silicon Valley.” As China’s only Special Medical Zone, it functions as a unique regulatory gateway for carefully selected and qualified international products, providing early access to one of the world’s most dynamic healthcare markets. Defined by its “First-in-Class” policy framework, the zone enables early introduction of advanced therapies and technologies, positioning it as a central hub for precision medicine and next-generation healthcare in Asia. Within this framework, GutMagnific® has been introduced at Boao Super Hospital as part of a clinical nutrition program supporting gut and systemic health.

“This milestone represents the culmination of nearly two years of focused regulatory work, scientific validation, and strategic execution,” said Shahram Lavasani, CEO and Founder of ImmuneBiotech.

“Establishing a presence within China’s most advanced medical innovation platform demonstrates both the scientific strength of our product and our ability to translate research into real-world clinical impact.”

Early Commercial Traction

Initial commercial shipments have been executed, demonstrating early market demand and marking the transition into active commercialization in China. This early traction provides initial validation of product–market fit and supports continued expansion as the company scales its presence within both clinical and consumer segments.

Clinical Integration and Research Collaboration

In parallel with its market entry, ImmuneBiotech has initiated clinical research in collaboration with Hainan Cancer Hospital, a leading oncology center in the region. The collaboration focuses on microbiome modulation in inflammation and immune regulation, as part of a broader strategy to further strengthen the clinical foundation of GutMagnific® in the Chinese market. This combined approach of clinical use and research reinforces ImmuneBiotech’s position at the forefront of microbiome-based healthcare innovation.

A High-Barrier Platform for Growth

ImmuneBiotech’s entry into China is underpinned by a robust and defensible strategic platform:

  • Regulatory access secured, following a rigorous regulatory process
  • Health claim approval achieved, differentiating the product from conventional probiotics
  • Chinese patent granted, strengthening long-term competitive positioning
  • Trademark registration completed, enabling scalable brand protection
  • Clinical and commercial infrastructure established

Together, these milestones represent a significant barrier to entry and position ImmuneBiotech for scalable, long-term growth in China.

Positioned in a Rapidly Expanding Market

China’s probiotic market, valued at approximately USD 2 billion, continues to grow rapidly, driven by increasing demand for preventive healthcare and rising awareness of gut health. Against this backdrop, ImmuneBiotech’s clinically oriented, precision-based approach positions the company to capture a differentiated segment of the market, bridging consumer health and clinical application.

“With regulatory access, clinical integration, and early commercial traction now established, we have built a strong foundation for expansion in China,” said Rickard Mosell, Chairman of the Board.

“This milestone represents an important step in scaling ImmuneBiotech into a global leader in precision microbiome-based health solutions.”

Official Recognition as a Leading Health Innovation

In April 2026, GutMagnific® was officially selected as one of only eight flagship “Health Innovation Products” presented at the China International Consumer Products Expo.
The selection was conducted through a rigorous expert evaluation process, positioning GutMagnific® among a highly curated group of next-generation medical and health innovations.
Notably, the selected products span advanced therapies and precision diagnostics, placing GutMagnific® within an exceptionally strong innovation context.
This recognition further reinforces the product’s positioning as a high-end medical health innovation, rather than a conventional food supplement.

Advancing Swedish Innovation into Global Markets

GutMagnific®, developed by ImmuneBiotech, is a clinically validated, multi-strain precision probiotic designed to restore gut microbiome balance, strengthen the intestinal barrier, and modulate immune function.
Building on its successful commercialization in Sweden, including national availability through Apoteket AB and MEDS Apotek, GutMagnific® is now expanding across EU markets and has established initial commercial traction in the United States, forming a foundation for further expansion as part of the company’s international scale-up strategy.

About ImmuneBiotech

ImmuneBiotech Medical Sweden AB is a Swedish biotechnology company based in Lund, focused on developing microbiome-based health solutions. With over two decades of research in immunology and the gut microbiome, the company is advancing a new category of precision probiotics targeting systemic health.

For further information, please contact:
Shahram Lavasani, CEO
ImmuneBiotech Medical Sweden AB
s.lavasani@immunebiotech.com
+46 700 90 8946
www.ImmuneBiotech.com
Learn more and purchase GutMagnific® at:
www.GutMagnific.com